Aimmune Therapeutics (AIMT) Stock Price, News & Analysis

Company Overview

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $34.49 to $34.49
• 50-Day Range: $34.30 to $34.59
• 52-Week Range: $10.09 to $37.00
• Volume: N/A
• Average Volume: 1.71 million shs
• Market Capitalization: $2.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AIMT Stock Analysis - Frequently Asked Questions

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.06).

When did Aimmune Therapeutics IPO?

Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Meta Platforms (META), Xtrackers California Municipal Bond ETF (CA) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 7/30/2020
• Today: 8/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AIMT
• CIK: 1631650
• Web: www.aimmune.com
• Phone: 650-614-5220
• Fax: N/A
• Employees: 228
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$248.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -164.99%
• Return on Assets: -89.50%

Debt

• Debt-to-Equity Ratio: 0.73
• Current Ratio: 7.53
• Quick Ratio: 7.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 20.78

Miscellaneous

• Outstanding Shares: 65,450,000
• Free Float: N/A
• Market Cap: $2.26 billion
• Optionable: Optionable
• Beta: 1.76